261 related articles for article (PubMed ID: 34157136)
61. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
62. Studies on glycogen storage disease type 1a animal models: a brief perspective.
Petrova IO; Smirnikhina SA
Transgenic Res; 2022 Dec; 31(6):593-606. PubMed ID: 36006546
[TBL] [Abstract][Full Text] [Related]
63. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
Chou JY; Jun HS; Mansfield BC
J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
[TBL] [Abstract][Full Text] [Related]
64. Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.
Clar J; Gri B; Calderaro J; Birling MC; Hérault Y; Smit GP; Mithieux G; Rajas F
Kidney Int; 2014 Oct; 86(4):747-56. PubMed ID: 24717294
[TBL] [Abstract][Full Text] [Related]
65. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.
Chou JY; Matern D; Mansfield BC; Chen YT
Curr Mol Med; 2002 Mar; 2(2):121-43. PubMed ID: 11949931
[TBL] [Abstract][Full Text] [Related]
66. The molecular basis of type 1 glycogen storage diseases.
Chou JY
Curr Mol Med; 2001 Mar; 1(1):25-44. PubMed ID: 11899241
[TBL] [Abstract][Full Text] [Related]
67. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse.
Lei KJ; Chen H; Pan CJ; Ward JM; Mosinger B; Lee EJ; Westphal H; Mansfield BC; Chou JY
Nat Genet; 1996 Jun; 13(2):203-9. PubMed ID: 8640227
[TBL] [Abstract][Full Text] [Related]
68. The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI.
Grünert SC; Hannibal L; Spiekerkoetter U
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440378
[TBL] [Abstract][Full Text] [Related]
69. [Heterogeneous phenotypes in Chinese glycogen storage disease type Ia patients with homozygous G727T mutation].
Qiu ZQ; Wei M; Liu G; Liu GY
Zhonghua Er Ke Za Zhi; 2003 Apr; 41(4):252-5. PubMed ID: 14754525
[TBL] [Abstract][Full Text] [Related]
70. The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice.
Rajas F; Dentin R; Cannella Miliano A; Silva M; Raffin M; Levavasseur F; Gautier-Stein A; Postic C; Mithieux G
Mol Metab; 2021 Jan; 43():101108. PubMed ID: 33137488
[TBL] [Abstract][Full Text] [Related]
71. A glycogen storage disease type 1a patient with type 2 diabetes.
Sun Y; Qiang W; Wu R; Yin T; Yuan J; Yuan J; Gu Y
BMC Med Genomics; 2022 Sep; 15(1):205. PubMed ID: 36167523
[TBL] [Abstract][Full Text] [Related]
72. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
[TBL] [Abstract][Full Text] [Related]
73. Mutations in the glucose-6-phosphatase gene are associated with glycogen storage disease types 1a and 1aSP but not 1b and 1c.
Lei KJ; Shelly LL; Lin B; Sidbury JB; Chen YT; Nordlie RC; Chou JY
J Clin Invest; 1995 Jan; 95(1):234-40. PubMed ID: 7814621
[TBL] [Abstract][Full Text] [Related]
74. Circulating exosomal microRNAs as potential biomarkers of hepatic injury and inflammation in a murine model of glycogen storage disease type 1a.
Resaz R; Cangelosi D; Morini M; Segalerba D; Mastracci L; Grillo F; Bosco MC; Bottino C; Colombo I; Eva A
Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32620541
[TBL] [Abstract][Full Text] [Related]
75. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
76. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
[TBL] [Abstract][Full Text] [Related]
77. Rapid Disruption of Genes Specifically in Livers of Mice Using Multiplex CRISPR/Cas9 Editing.
Pankowicz FP; Barzi M; Kim KH; Legras X; Martins CS; Wooton-Kee CR; Lagor WR; Marini JC; Elsea SH; Bissig-Choisat B; Moore DD; Bissig KD
Gastroenterology; 2018 Dec; 155(6):1967-1970.e6. PubMed ID: 30170115
[TBL] [Abstract][Full Text] [Related]
78. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.
Grefhorst A; Schreurs M; Oosterveer MH; Cortés VA; Havinga R; Herling AW; Reijngoud DJ; Groen AK; Kuipers F
Biochem J; 2010 Dec; 432(2):249-54. PubMed ID: 20854262
[TBL] [Abstract][Full Text] [Related]
79. Genetic heterogeneity of glycogen storage disease type Ia in France: a study of 48 patients.
Trioche P; Francoual J; Chalas J; Capel L; Lindenbaum A; Odièvre M; Labrune P
Hum Mutat; 2000 Nov; 16(5):444. PubMed ID: 11058903
[TBL] [Abstract][Full Text] [Related]
80. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
